Join Enanta in supporting the World Hepatitis Alliance on World Hepatitis Day, July 28, 2014.

From Chemistry to Cures

An estimated 150 million people worldwide are chronically infected with HCV

From Chemistry to Cures

More than 350,000 people die every year from HCV-related liver diseases

From Chemistry to Cures

The CDC estimated approximately 3.2 million people
in the U.S. are chronically infected with HCV

From Chemistry to Cures

ABOUT ENANTA

We are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. We are discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV. Learn more about us.

Our Vision

Our primary objective is to become a leader in the infectious disease field, with a focus on HCV and multi-drug-resistant bacterial infections. Learn more.

Our Research

We are pursuing four fundamental, validated targets within the HCV field that represent a broad approach to the disease and specifically address the urgent unmet medical needs for the treatment of HCV. Learn more.